Future Science Group
Supplementary Figure 2.tif (2.44 MB)

imt-2021-0013 - Supplementary Material - Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models

Download (2.44 MB)
posted on 2021-09-08, 10:52 authored by Figshare Future Science GroupFigshare Future Science Group, Eduardo Huarte, Michael Peel, Ashish Juvekar, Philip Dubé, Sarala Sarah, Lynn Stephens, Becky Stewart, Brian Long, Philip Czerniak, Julian Oliver, Paul Smith

Supplementary Figure 2. hIL-15 NOG model characterization. hIL-15 NOG mice were engrafted with 1 × 106, 2.5 × 106 or 5 × 106 human PBMCs and monitored for GvHD progression. Flow cytometry was performed to profile the engraftment of cell populations, indicating that all PBMC doses resulted in engraftment of CD45+ lymphocytes (A), with CD3+ T-, CD56+ NK and CD3+/CD56+ NK-T cell engraftment as well (B). Monitoring of changes in body weight, GvHD score and survival (C–E) indicated that the highest dose of PBMCs led to the most aggressive form of GvHD, and thus this dosage was chosen for all further studies using this model. Data are presented as mean ± SEM. n = 10 mice per group.

GvHD: graft-versus-host disease; NK: natural killer; PBMC: peripheral blood mononuclear cell; SEM: standard error of the mean.


Incyte Corporation